	СТА		
Scanner	Siemens, SOMATOM Definition AS+ and Edge		
Detector collimation (mm)	128 x 0.6		
Reconstruction slice thickness (mm)	1.0		
Reconstruction interval (mm)	0.5		
Scan phase	Intravenous contrast agent, 3-sec delay		
Table speed (mm/s)	5		
Pitch	1		
Rotation time (s)	0.5		
Tube voltage (kV/mAs)	120/300		
Contrast agent	Iopamidol-based nonionic contrast (Pamiray370 [®])		
Iodine concentration (mg/mL)	370		
Flow rate (mL/s)	4.5		
Contrast agent volume (mL)	60		
Staring location	Aortic root		
Ending location	3cm above the skull		
CTDI dosimetry phantom diameter (cm)	32		
Mean CTDI volume (mGy)	$69.6\pm26.5\ L$		
1st quartile	47 L		
Median	74 L		
3rd quartile	84 L		
Mean DLP (mGy \times cm)	2170 ± 827.6		
1st quartile	1500		
Median	2177		
3rd quartile	2652		
Soft tissue Kernel	B40		

Online Table 1. CTA acquisition parameters

CTDI, computed tomography dose index; DLP, dose-length product

Online Table 2. Cox proportional hazards model for the association of the plaque HU values with the occurrence of the MACE composite outcome and the individual MACE components among subjects with moderate CAS (*n*=101)

	MACE (-)	MACE (+)	HR (95% CI)	P value
MACE ^a (n=18)	39.6 ± 15.7	27.6 ± 8.6	0.95 (0.92–0.98)	.002
Any stroke (<i>n</i> =8)	38.5 ± 15.3	25.0 ± 11.6	0.95 (0.90-0.99)	.01
Ipsilateral stroke (<i>n</i> =6)	38.2 ± 15.4	25.3 ± 11.0	0.95 (0.90-0.99)	.04
ACS (<i>n</i> =7)	38.1 ± 15.7	29.6 ± 6.1	0.96 (0.92–1.01)	.14
Cardiovascular mortality (n=8)	38.3 ± 15.7	27.5 ± 6.6	0.95 (0.91–0.99)	.04
All-cause mortality (<i>n</i> =23)	38.3 ± 15.7	34.8 ± 14.3	0.99 (0.96–1.01)	.31

Data are presented as means \pm standard deviations of plaque HU values.

ACS, acute coronary syndrome; CAS, carotid artery stenosis; HR, hazard ratio; HU, Hounsfield unit;

MACE, major adverse cardiovascular event

^aAny stroke, ACS, or cardiovascular mortality

Online Table 3. Cox proportional hazards model for the association of the presence of spotty calcium on CTA with the occurrence of the MACE composite outcome and the individual MACE components among subjects with moderate CAS (*n*=101)

	MACE (-)	MACE (+)	HR (95% CI)	P value
MACE ^a (n=18)	11 (13.3)	8 (44.4)	5.20 (1.94–13.92)	.001
Any stroke (<i>n</i> =8)	16 (17.2)	3 (37.5)	4.07 (0.91–18.31)	.07
Ipsilateral stroke (n=6)	16 (16.8)	3 (50.0)	5.48 (1.10-27.37)	.04
ACS (<i>n</i> =7)	15 (16.0)	4 (57.1)	6.93 (1.52–31.58)	.01
Cardiovascular mortality (n=8)	15 (16.1)	4 (50.0)	4.34 (1.08–17.40)	.04
All-cause mortality (<i>n</i> =23)	10 (12.8)	9 (39.1)	2.72 (1.17-6.31)	.02


Data are presented as n (%) of carotid plaques with spotty calcium detected on CTA.

ACS, acute coronary syndrome; CAS, carotid artery stenosis; HR, hazard ratio; MACE, major adverse cardiovascular event

^aAny stroke, ACS, or cardiovascular mortality

Online Fig 1. Flow chart of carotid plaque inclusion

The analysis included 194 carotid plaques identified in 176 asymptomatic subjects with moderate to severe CAS, diagnosed using CTA and additional Doppler ultrasound. The associations between various demographic, clinical, and imaging features and subsequent MACE occurrence were evaluated. CAS, carotid artery stenosis; CEA, carotid endarterectomy; MACE, major adverse cardiovascular event ^aSubjects with recent cardiovascular events within 6 months



Online Fig 2. Boxplot of the degree of CAS on baseline CTA and additional Doppler ultrasound imaging

The distribution of the degree of CAS values revealed no significant difference between the non-MACE and MACE groups.

CAS, carotid artery stenosis; IQR, interquartile range; MACE, major adverse cardiovascular event

